New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 19, 2012
09:59 EDTSQNM, WLPWellpoint deems Sequenom pre-natal tests medically necessary for some patients
In a medical policy update with an effective date of Dec. 19, 2012, health insurer Wellpoint (WLP) stated that it views cell-free fetal DNA-based prenatal screening for fetal aneuploidies, including but not limited to Trisomy 13, Trisomy 18 and Trisomy 21, medically necessary for its members when certain criteria are met. Wellpoint stated there are currently several commercially available laboratory developed tests which analyze circulating cell-free DNA to identify increased representation of various chromosomes, including but not necessarily limited to the Sequenom's (SQNM) MaterniT21 Test and its MaterniT21 Plus Test, among others from Verinata Health and Aria Diagnostics. In early morning trading, shares of Sequenom rose 32c, or 6.84%, to $4.96, with the strength being attributed by some to Wellpoint's approval. Reference Link
News For SQNM;WLP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
07:40 EDTWLPExpress Scripts price target raised to $96 from $82 at UBS
Subscribe for More Information
December 10, 2014
14:45 EDTWLPDeal would block payments to health insurance companies, The Hill says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use